TSHATaysha Gene Therapies, Inc.
$4.49+59% 1Y
$4.49
$2.8752 weeks$6.98
TSHA in its own filings
TSHA's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
143
Events found in the filings · across 401 filings · the record starts in 2020
- Hard flags
- 1
Hard flags
- Most recent filing
- Aug 11, 2026
Most recent filing · Form 10-Q
- Record starts
- Sep 2, 2020
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 3, 2026
- Delisting notice / listing-rule failure2 occurrences
- 2023-08-04
- SEC comment-letter activity15 occurrences
- 2024-12-20
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 11, 2026Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
- Jun 25, 2026On June 24, 2026, Taysha Gene Therapies, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Goldman Sachs & Co. LLC, as representatives of the several underwriters set forth therein (collectively, the “Underwriters”), to issue and sell 32,500,001 shares of …Material agreement entered · Form 8-K
- Jun 22, 2026Clinical and Regulatory Update Presentation On June 22, 2026, the Company also made available a presentation to be used to discuss the clinical and regulatory updates on TSHA-102.Regulation FD disclosure · Form 8-K
- May 6, 2026Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
- Mar 19, 2026Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update.Earnings release · press release
- Nov 4, 2025As previously disclosed, Taysha Gene Therapies, Inc. (the “Company”) is party to that certain Sales Agreement, dated October 5, 2021, as amended by that certain Amendment No. 1, dated March 30, 2022 (as so amended, the “Sales Agreement”), with Goldman Sachs & Co. LLC, Wells Fargo Securities, LLC and Leerink Partners …Material agreement entered · Form 8-K
- Oct 16, 2025Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the.Other event · press release
- Oct 9, 2025Taysha Gene Therapies Presents New Supplemental Data Analysis from Part A of the REVEAL Phase.Other event · press release
- Oct 2, 2025Taysha Gene Therapies Announces FDA Breakthrough Therapy Designation and Provides Positive Regulatory Update on TSHA-102 in Rett Syndrome.Other event · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
On our screens:Most shorted stocks